Skip to content

Study · Non-randomized trial · 2025

12 results

Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.

Liu C, Xin Y, Huang Y, Xu L, Zhou R, Wang Y, Wang W

Endocrinology, diabetes & metabolism1 Jan 2025Cited by 4 (Europe PMC)

PMID39718468 (opens in a new tab)PMCIDPMC11667988 (opens in a new tab)DOI10.1002/edm2.70021 (opens in a new tab)PepBankPUB-39718468
Download PDFPubMedAsk about this study
Jump to 12 results

Summary

BackgroundWith the elevated level of NAFLD prevalence, the incidence of diabetes, hypertension, metabolic syndrome and other diseases is also significantly elevated. GLP-1RA can exert weight loss, glucose-lowering effects and various nonglycaemic effects. However, the relationship between quantitative reduction in hepatic fat content and improvement of pancreatic islet function by GLP-1RA is unclear.MethodsThis trial was a single-arm open cohort study. A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group. The included patients were tested for biochemical and blood glucose levels, adiponectin and FGF21 levels, and liver fat content was measured using MRI. Measure the above indicators again after at least 3 months of GLP-1RA treatment. Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.ResultsQ2 group showed an average reduction in liver fat content of 8.6%, a decrease in glycated haemoglobin of 18.17%, a weight loss of 7.29% and an increase in fasting c-peptide release by 1.03%, 1-h and 2-h postprandial c-peptide release by 28.86% and 18.28% respectively. In contrast, Q1 group had an average reduction in liver fat content of 0.37%, a decrease in glycated haemoglobin of only 6.53%, a weight loss of 3.41%, a decrease in fasting c-peptide release by 1.91% and an increase in 1-h and 2-h postprandial c-peptide release by 19.18% and 11.66% respectively.ConclusionReduction in liver fat content effectively improves pancreatic islet function secretion, particularly postprandial c-peptide secretion, especially in the first hour after a meal. This improvement leads to a decrease in glycated haemoglobin levels and promotes better compliance with blood glucose control.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q2 liver fat content decreased by 8.6% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, liver fat fell 8.6% from baseline in Q2.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseLiver fat reduction in Q2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Liver fat reduction
    8.6%
    Q2

    Source sentences

    Summary
    Q2 group showed an average reduction in liver fat content of 8.6%, a decrease in glycated haemoglobin of 18.17%, a weight loss of 7.29% and an increase in fasting c-peptide release by 1.03%, 1-h and 2-h postprandial c-peptide release by 28.86% and 18.28% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q2 glycated haemoglobin decreased by 18.17% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, glycated haemoglobin fell 18.17% from baseline in Q2.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction in Q2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Glycated haemoglobin reduction
    18.17%
    Q2

    Source sentences

    Summary
    Q2 group showed an average reduction in liver fat content of 8.6%, a decrease in glycated haemoglobin of 18.17%, a weight loss of 7.29% and an increase in fasting c-peptide release by 1.03%, 1-h and 2-h postprandial c-peptide release by 28.86% and 18.28% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q2 body weight decreased by 7.29% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, weight fell 7.29% from baseline in Q2.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight loss in Q2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Weight loss
    7.29%
    Q2

    Source sentences

    Summary
    Q2 group showed an average reduction in liver fat content of 8.6%, a decrease in glycated haemoglobin of 18.17%, a weight loss of 7.29% and an increase in fasting c-peptide release by 1.03%, 1-h and 2-h postprandial c-peptide release by 28.86% and 18.28% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q2 fasting c-peptide release increased by 1.03% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, fasting c-peptide release rose 1.03% from baseline in Q2.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFasting c-peptide release in Q2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Fasting c-peptide release increase
    1.03%
    Q2

    Source sentences

    Summary
    Q2 group showed an average reduction in liver fat content of 8.6%, a decrease in glycated haemoglobin of 18.17%, a weight loss of 7.29% and an increase in fasting c-peptide release by 1.03%, 1-h and 2-h postprandial c-peptide release by 28.86% and 18.28% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q2 one-hour postprandial c-peptide release increased by 28.86% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, one-hour post-meal c-peptide release rose 28.86% from baseline in Q2.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseOne-hour postprandial c-peptide release in Q2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Postprandial c-peptide release increase
    28.86%
    Q2, 1-h

    Source sentences

    Summary
    Q2 group showed an average reduction in liver fat content of 8.6%, a decrease in glycated haemoglobin of 18.17%, a weight loss of 7.29% and an increase in fasting c-peptide release by 1.03%, 1-h and 2-h postprandial c-peptide release by 28.86% and 18.28% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q2 two-hour postprandial c-peptide release increased by 18.28% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, two-hour post-meal c-peptide release rose 18.28% from baseline in Q2.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTwo-hour postprandial c-peptide release in Q2
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Postprandial c-peptide release increase
    18.28%
    Q2, 2-h

    Source sentences

    Summary
    Q2 group showed an average reduction in liver fat content of 8.6%, a decrease in glycated haemoglobin of 18.17%, a weight loss of 7.29% and an increase in fasting c-peptide release by 1.03%, 1-h and 2-h postprandial c-peptide release by 28.86% and 18.28% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q1 liver fat content decreased by 0.37% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, liver fat fell 0.37% from baseline in Q1.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseLiver fat reduction in Q1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Liver fat reduction
    0.37%
    Q1

    Source sentences

    Summary
    In contrast, Q1 group had an average reduction in liver fat content of 0.37%, a decrease in glycated haemoglobin of only 6.53%, a weight loss of 3.41%, a decrease in fasting c-peptide release by 1.91% and an increase in 1-h and 2-h postprandial c-peptide release by 19.18% and 11.66% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q1 glycated haemoglobin decreased by 6.53% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, glycated haemoglobin fell 6.53% from baseline in Q1.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction in Q1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Glycated haemoglobin reduction
    6.53%
    Q1

    Source sentences

    Summary
    In contrast, Q1 group had an average reduction in liver fat content of 0.37%, a decrease in glycated haemoglobin of only 6.53%, a weight loss of 3.41%, a decrease in fasting c-peptide release by 1.91% and an increase in 1-h and 2-h postprandial c-peptide release by 19.18% and 11.66% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q1 body weight decreased by 3.41% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, weight fell 3.41% from baseline in Q1.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight loss in Q1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Weight loss
    3.41%
    Q1

    Source sentences

    Summary
    In contrast, Q1 group had an average reduction in liver fat content of 0.37%, a decrease in glycated haemoglobin of only 6.53%, a weight loss of 3.41%, a decrease in fasting c-peptide release by 1.91% and an increase in 1-h and 2-h postprandial c-peptide release by 19.18% and 11.66% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  10. 10HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q1 fasting c-peptide release decreased by 1.91% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, fasting c-peptide release fell 1.91% from baseline in Q1.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting c-peptide release in Q1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Fasting c-peptide release decrease
    1.91%
    Q1

    Source sentences

    Summary
    In contrast, Q1 group had an average reduction in liver fat content of 0.37%, a decrease in glycated haemoglobin of only 6.53%, a weight loss of 3.41%, a decrease in fasting c-peptide release by 1.91% and an increase in 1-h and 2-h postprandial c-peptide release by 19.18% and 11.66% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  11. 11HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q1 one-hour postprandial c-peptide release increased by 19.18% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, one-hour post-meal c-peptide release rose 19.18% from baseline in Q1.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseOne-hour postprandial c-peptide release in Q1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Postprandial c-peptide release increase
    19.18%
    Q1, 1-h

    Source sentences

    Summary
    In contrast, Q1 group had an average reduction in liver fat content of 0.37%, a decrease in glycated haemoglobin of only 6.53%, a weight loss of 3.41%, a decrease in fasting c-peptide release by 1.91% and an increase in 1-h and 2-h postprandial c-peptide release by 19.18% and 11.66% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
  12. 12HumanNon-randomized trialEfficacy outcome

    In patients with T2DM and NAFLD receiving dulaglutide, Q1 two-hour postprandial c-peptide release increased by 11.66% versus baseline.

    In plain wordsIn patients with diabetes and fatty liver receiving dulaglutide, two-hour post-meal c-peptide release rose 11.66% from baseline in Q1.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTwo-hour postprandial c-peptide release in Q1
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least 3 monthsAs given in this study (human).

    Measurements

    Postprandial c-peptide release increase
    11.66%
    Q1, 2-h

    Source sentences

    Summary
    In contrast, Q1 group had an average reduction in liver fat content of 0.37%, a decrease in glycated haemoglobin of only 6.53%, a weight loss of 3.41%, a decrease in fasting c-peptide release by 1.91% and an increase in 1-h and 2-h postprandial c-peptide release by 19.18% and 11.66% respectively.
    5 context sentences
    Summary · context
    This trial was a single-arm open cohort study.
    Summary · context
    A total of 38 patients with T2DM and NAFLD were enrolled in the GLP-1RA treatment group.
    Summary · context
    Measure the above indicators again after at least 3 months of GLP-1RA treatment.
    Summary · context
    Divided into Q1 (average decrease of 0.37%) and Q2 (average decrease of 8.6%) groups based on the degree of reduction in liver fat content.
    Title · context
    Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.